As part of a new strategic initiative, aimed at strengthening its presence in cranberry derivatives, Indena has entered an industrial and commercial agreement with Pharmatoka.
On the basis of this agreement, Indena will produce GIKACRAN® under exclusive license for Pharmatoka and will directly market GIKACRAN in Japan, South Korea, China, India and Russia.
GIKACRAN is a well-characterized cranberry juice (Vaccinium macrocarpon Ait.) extract, standardized so as to provide 17 to 22 percent total proanthocyanidin (PAC) measured by DMAC method. Just 200 mg of GIKACRAN, containing 36 mg of cranberry PACs, provide the same amount of PACs as found in 40 g of fresh fruits. GIKACRAN has been used since 2006 in different dietary supplement products in and outside Europe under the brand names URELL and ELLURA. It is also available in Malaysia as a traditional herbal medicine and in Australia as a complementary listed medicine.
“Indena and Pharmatoka share the mission to improve health and well-being for people worldwide, summarized in our four principles,” said Gunter Haesaerts, CEO and founder of Pharmatoka. “Scientific support, close relationships with health professionals, continuous listening to our customers and excellence of our products are what we commit to, and Indena is an excellent partner.”
Commenting on the news, Christian Artaria, marketing director of Indena, said: “We are excited to start the commercialization of GIKACRAN in these countries in which we have an historical important presence, and Japan is the first market we will approach. We strongly believe in GIKACRAN and in its potential, and we are really confident that our product will clearly distinguish from any other cranberry extract on the market”.